News & Views
Large-Scale COVID-19 Vaccine Manufacture Deal Agreed
Dec 11 2020
AstraZeneca AB has signed an agreement with Netherlands-based HALIX B.V for large-scale commercial drug substance manufacture of AZD1222, the adenovirus vector-based COVID-19 vaccine, co-invented by the University of Oxford and its spin-out company Vaccitech.
Under the agreement, HALIX, one of the original partners in the University of Oxford’s consortium, will provide commercial manufacturing of drug substance at its cGMP facility at the Leiden Bio Science Park in the Netherlands, which has been expanded with two additional viral vector production lines.
Alex Huybens, Chief Operations Officer, states, “Building on the solid foundations made with the University of Oxford, it’s our pleasure to expand our manufacturing support of AZD1222 with AstraZeneca. Through the consortium, the partners are bringing their collective expertise and manufacturing capabilities to support vaccine production and combat this evolving crisis.”
HALIX has an established track record for the development and GMP manufacture of viral vectors used in immuno-oncology and to vaccinate against infectious diseases, such as HIV, ZIKA, Chikungunya and the Influenza. Its 6,700 m2 BSL2 GMP facility at Leiden Bio Science Park, recently approved by the Dutch authorities, provides both clinical and commercial scale manufacturing capabilities in fully independent, self-contained Grade B and C cleanrooms for virus products. The company belongs to the family owned Droege Group AG.
More information: online
Digital Edition
International Labmate 49.6 - Sept 2024
September 2024
Chromatography Articles - HPLC gradient validation using non-invasive flowmeters Mass Spectrometry & Spectroscopy Articles - From R&D to QC, making NMR accessible for everyone: Putting NMR...
View all digital editions
Events
Sep 22 2024 Messina, Italy
19th Confocal Raman Imaging Symposium
Sep 23 2024 Ulm, Germany
Sep 24 2024 Kielce, Poland
WoTS - World of Technology and Science
Sep 24 2024 Utrecht, Holland
Sep 25 2024 Frankfurt am Main, Germany